Medpace Holdings Inc

MEDP

Equity

ISIN null / Valor 33038552

NASDAQ (2025-12-19)

USD 568.36+1.45%

Medpace Holdings Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Medpace Holdings Inc. is a full-service clinical contract research organization (CRO) that specializes in providing comprehensive research and development services for the biotechnology, pharmaceutical, and medical device industries. With over three decades of experience, Medpace adopts a high-science, disciplined operating approach that emphasizes regulatory and therapeutic expertise across all major therapeutic areas. The company distinguishes itself through its collaborative teams of medical, operational, and regulatory experts who possess deep knowledge and insights into specific diseases and patient demographics targeted by clinical trials. Medpace's extensive experience also facilitates strong relationships with Key Opinion Leaders, Principal Investigators, and high-performing sites, which in turn helps to accelerate the clinical development process. The organization offers a wide range of services, including global cardiac safety and imaging through its Medpace Core Labs, as well as comprehensive CRO services supported by wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab, and a Phase I Unit. These services are integrated with a Clinical Trial Management System to streamline clinical trials, enhancing efficiency and productivity for biotech companies seeking to expedite the development of medical therapeutics.

Summarized from source with an LLMView SourceSector: Technology

Revenue & New Business Growth

For Q3 2025, Medpace Holdings Inc achieved revenues of $659.9 million, up 23.7% from $533.3 million in Q3 2024. Net new business awards surged by 47.9% to $789.6 million, resulting in a robust net book-to-bill ratio of 1.20x, highlighting the company’s strong pipeline conversion.

Improved Profitability

GAAP net income for the quarter increased to $111.1 million (or $3.86 per diluted share) from $96.4 million (or $3.01 per diluted share) in Q3 2024, although the net income margin declined slightly from 18.1% to 16.8%. This improvement in earnings underscores Medpace Holdings Inc’s successful cost management and revenue growth.

EBITDA Performance

Q3 2025 EBITDA reached $148.4 million, marking a 24.9% increase from $118.8 million in the prior-year period and achieving a margin of 22.5%. These strong EBITDA figures reinforce the company’s operational efficiency and its ability to scale its services effectively.

Summarized from source with an LLMView Source

Key figures

69.6%1Y

183%3Y

306%5Y

Performance

57.5%1Y

46.8%3Y

47.9%5Y

Volatility